LB Pharmaceuticals (LBRX) Q2 2026 earnings summary

Executive summary

• LB-102, a novel benzamide antipsychotic, is in late-stage clinical trials for schizophrenia and bipolar depression, with additional trials planned for major depressive disorder and other neuropsychiatric indications.

• Accelerated topline data readout for pivotal Phase 3 NOVA-2 trial in schizophrenia now expected in H1 2027, ahead of prior guidance.

• No product revenue to date; operations funded by IPO and private placements totaling over $549 million in gross proceeds since inception.

• $150 million private placement completed in July 2026 to fund pipeline expansion and operations through multiple clinical milestones beyond Q2 2029.

• Net loss of $70.7 million for the six months ended June 30, 2026, with an accumulated deficit of $200.2 million.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $327.8 million as of June 30, 2026, excluding $150 million private placement proceeds.

• Research and development expenses rose to $58.8 million for the six months ended June 30, 2026, up from $5.8 million year-over-year, driven by clinical trial activity.

• General and administrative expenses increased to $17.2 million from $5.4 million year-over-year, reflecting higher stock-based compensation, headcount, and public company costs.

• Net loss per share was $(2.42) for the six months ended June 30, 2026, compared to $(28.36) for the same period in 2025, reflecting a significant increase in shares outstanding post-IPO.

• Non-operating income of $5.4 million for the six months ended June 30, 2026, primarily from interest income on higher cash balances.

Outlook and guidance

• Topline data from pivotal Phase 3 schizophrenia trial expected H1 2027; pre-NDA meeting with FDA planned for H2 2027.

• Phase 2 ILLUMINATE-1 trial in bipolar 1 depression enrolling, with topline data expected in Q1 2028.

• Phase 2 trial in adjunctive MDD to initiate in early 2027, with topline data expected in H1 2029.

• Cash resources, including July 2026 private placement, expected to fund operations beyond Q2 2029.

• Anticipates continued operating losses and increased expenses as clinical programs advance and organization scales for potential commercialization.